Oral Solid Dosage Pharmaceutical Formulation

Global Oral Solid Dosage Pharmaceutical Formulation Market to Reach US$818.6 Million by 2030

The global market for Oral Solid Dosage Pharmaceutical Formulation estimated at US$668.0 Million in the year 2024, is expected to reach US$818.6 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Tablets Form, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$280.1 Million by the end of the analysis period. Growth in the Capsules Form segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$182.0 Million While China is Forecast to Grow at 6.3% CAGR

The Oral Solid Dosage Pharmaceutical Formulation market in the U.S. is estimated at US$182.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Oral Solid Dosage Pharmaceutical Formulation Market – Key Trends & Drivers Summarized

Why Do Oral Solid Dosage Forms Remain the Cornerstone of Pharmaceutical Drug Delivery Systems?

Oral Solid Dosage (OSD) forms—primarily tablets, capsules, and powders—continue to dominate global pharmaceutical formulations due to their ease of administration, cost-effectiveness, high patient compliance, and manufacturing scalability. Despite growing interest in biologics and parenterals, OSDs account for over 50% of global pharmaceutical prescriptions. Their stability, controlled-release potential, and long shelf life make them especially advantageous for chronic therapy regimens and large-scale distribution, particularly in low- and middle-income markets.

The versatility of OSD formats supports an expansive range of therapeutic categories including cardiovascular, anti-infective, CNS, oncology, and gastrointestinal treatments. The rise in chronic disease prevalence, geriatric population, and demand for personalized medicine further reinforces the relevance of OSDs. Recent innovations—such as orally disintegrating tablets (ODTs), abuse-deterrent formulations, and multi-particulate capsules—are addressing challenges related to pediatric and geriatric adherence, dosage titration, and bioavailability, ensuring that OSDs remain the foundation of global drug delivery systems.

How Are Formulation Science and Manufacturing Technologies Enhancing the Efficiency of OSD Development?

Advancements in formulation technologies have significantly improved the performance, stability, and release profiles of oral solid dosage drugs. Hot melt extrusion, spray drying, and nano-milling are enabling the development of OSDs for poorly soluble Active Pharmaceutical Ingredients (APIs), addressing the growing Biopharmaceutics Classification System (BCS) class II and IV drug portfolios. Modified-release technologies, including extended-release, delayed-release, and pulsatile systems, are being deployed to improve therapeutic windows and reduce dosing frequency.

Manufacturers are increasingly adopting continuous manufacturing, Process Analytical Technology (PAT), and Quality by Design (QbD) principles to enhance production efficiency, reduce cycle times, and ensure consistent quality. Automated tablet compression, real-time monitoring, and advanced granulation methods are improving batch-to-batch reproducibility and reducing material wastage. Moreover, 3D printing is being explored for patient-specific dosage customization and multi-drug combinations. These innovations are not only expanding formulation flexibility but also streamlining regulatory approvals and accelerating time-to-market.

Which Therapeutic Areas and Regional Markets Are Driving Demand for OSD Pharmaceutical Formulations?

OSDs are extensively used across a wide array of therapeutic segments, but their dominance is particularly pronounced in chronic disease management. Hypertension, diabetes, depression, epilepsy, and infectious diseases are among the top drivers of volume-based OSD production globally. Oncology and autoimmune segments are also increasingly utilizing oral targeted therapies and kinase inhibitors in solid dosage formats, improving outpatient treatment protocols.

North America and Europe remain the leading markets, supported by advanced manufacturing facilities, regulatory expertise, and high prescription drug usage. The Asia-Pacific region, led by India and China, is experiencing the fastest growth in OSD production due to rising healthcare access, domestic pharmaceutical industry expansion, and strong export infrastructure. Latin America, the Middle East, and Africa are seeing growing adoption through public health initiatives, generics penetration, and increased domestic manufacturing capacity. These regions represent high potential for volume growth, especially for essential medicines in tablet or capsule form.

What Is Powering Long-Term Growth and Strategic Innovation in the OSD Formulations Market?

The growth in the oral solid dosage pharmaceutical formulation market is driven by increasing demand for cost-effective therapies, generics substitution, and long-term treatment adherence in chronic conditions. With payers and governments pushing for affordable healthcare solutions, OSDs remain the preferred format for formulary inclusion and reimbursement. Patent expiries are also creating robust opportunities for generic and branded-generic OSD products across global markets.

Strategic innovation is focused on fixed-dose combinations (FDCs), taste-masked pediatric formulations, and patient-centric packaging. Companies are developing multi-layer tablets, multiparticulate delivery systems, and film-coated formats to enhance swallowing, stability, and drug release dynamics. Sustainability is emerging as a priority, with biodegradable packaging and greener synthesis methods gaining traction. As pharmacogenomics and individualized dosing evolve, OSDs are expected to adapt through modular dosing platforms and digital integration, ensuring their continued dominance in the global pharmaceutical landscape.

SCOPE OF STUDY:

The report analyzes the Oral Solid Dosage Pharmaceutical Formulation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Dosage Form (Tablets, Capsules, Powders, Lozenges & Pastilles, Gummies); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Aenova Group
• Alcami Corporation
• Almac Group
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Catalent Inc.
• CordenPharma International
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Lonza Group AG
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.